Artiva Biotherapeutics, Inc. Common Stock
ARTVArtiva Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf natural killer (NK) cell therapies for cancer treatment. The company aims to leverage its proprietary platforms to create innovative immunotherapies that enhance the body's immune response against tumors. Founded with a focus on advancing cell therapy technologies, Artiva is dedicated to addressing unmet needs in oncology.
$3.21 +0.08 (2.40%)
Company News
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics reported treating over 100 patients with AlloNK across autoimmune and oncology indications, receiving FDA Fast Track Designation for refractory rheumatoid arthritis treatment. The company expects initial clinical response data in first half of 2026 and has $123 million cash runway into Q2 2027.
